These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

18 related articles for article (PubMed ID: 3488347)

  • 1. Multisite Kinetic Modeling of (13)C Metabolic MR Using [1-(13)C]Pyruvate.
    Gómez Damián PA; Sperl JI; Janich MA; Khegai O; Wiesinger F; Glaser SJ; Haase A; Schwaiger M; Schulte RF; Menzel MI
    Radiol Res Pract; 2014; 2014():871619. PubMed ID: 25548671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of alanine aminotransferase in silico and in vivo promotes mitochondrial metabolism to impair malignant growth.
    Beuster G; Zarse K; Kaleta C; Thierbach R; Kiehntopf M; Steinberg P; Schuster S; Ristow M
    J Biol Chem; 2011 Jun; 286(25):22323-30. PubMed ID: 21540181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice.
    Zierhut ML; Yen YF; Chen AP; Bok R; Albers MJ; Zhang V; Tropp J; Park I; Vigneron DB; Kurhanewicz J; Hurd RE; Nelson SJ
    J Magn Reson; 2010 Jan; 202(1):85-92. PubMed ID: 19884027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex.
    Mazurek S; Zwerschke W; Jansen-Dürr P; Eigenbrodt E
    Biochem J; 2001 May; 356(Pt 1):247-56. PubMed ID: 11336658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alanine inhibits cytotoxic responses: its production by different tumor cell lines explains differences in their immunogenicity.
    Dröge W; Wehrmaker A; Eck HP
    Cancer Detect Prev; 1988; 11(3-6):151-6. PubMed ID: 3134127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity).
    Wehrmaker A; Lehmann V; Dröge W
    Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capacity of different cell types to stimulate cytotoxic T lymphocyte precursor cells in the presence of interleukin 2.
    Dröge W; Moyers C; Wehrmaker A; Schmidt H; Panknin S; Männel D; Falk W
    J Immunol; 1984 Jun; 132(6):2749-59. PubMed ID: 6233360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of cytotoxic T-lymphocyte activation by L-lactate and pyruvate.
    Mihm S; Dröge W
    Cell Immunol; 1985 Nov; 96(1):235-40. PubMed ID: 2941155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
    Kaido TJ; Maury C; Gresser I
    Cancer Res; 1995 Dec; 55(24):6133-9. PubMed ID: 8521404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of L-alanine by tumor cells.
    Dröge W; Eck HP; Kriegbaum H; Mihm S
    J Immunol; 1986 Aug; 137(4):1383-6. PubMed ID: 3488347
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.